These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 24789032)

  • 1. Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies.
    Lovly CM; Shaw AT
    Clin Cancer Res; 2014 May; 20(9):2249-56. PubMed ID: 24789032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combating acquired resistance to tyrosine kinase inhibitors in lung cancer.
    Lovly CM
    Am Soc Clin Oncol Educ Book; 2015; ():e165-73. PubMed ID: 25993168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: A review.
    Yang K; Fu LW
    Crit Rev Oncol Hematol; 2015 Mar; 93(3):277-92. PubMed ID: 25500000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors.
    Yu HA; Riely GJ; Lovly CM
    Clin Cancer Res; 2014 Dec; 20(23):5898-907. PubMed ID: 25303979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategies to overcome resistance to targeted protein kinase inhibitors in the treatment of cancer.
    Buschbeck M
    Drugs R D; 2006; 7(2):73-86. PubMed ID: 16542054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.
    Ali MA
    Mol Diagn Ther; 2016 Aug; 20(4):315-33. PubMed ID: 27220498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma.
    Lim SY; Menzies AM; Rizos H
    Cancer; 2017 Jun; 123(S11):2118-2129. PubMed ID: 28543695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anaplastic Lymphoma Kinase as a Therapeutic Target in Non-Small Cell Lung Cancer.
    Iams WT; Lovly CM
    Cancer J; 2015; 21(5):378-82. PubMed ID: 26389762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
    Walz C; Sattler M
    Crit Rev Oncol Hematol; 2006 Feb; 57(2):145-64. PubMed ID: 16213151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enigmas in tumor resistance to kinase inhibitors and calculation of the drug resistance index for cancer (DRIC).
    Smith CIE
    Semin Cancer Biol; 2017 Aug; 45():36-49. PubMed ID: 27865897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Durability of Kinase-Directed Therapies--A Network Perspective on Response and Resistance.
    Murray BW; Miller N
    Mol Cancer Ther; 2015 Sep; 14(9):1975-84. PubMed ID: 26264276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
    Zhang K; Yuan Q
    J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors.
    Patel AB; O'Hare T; Deininger MW
    Hematol Oncol Clin North Am; 2017 Aug; 31(4):589-612. PubMed ID: 28673390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Receptor Tyrosine Kinase-Targeted Cancer Therapy.
    Yamaoka T; Kusumoto S; Ando K; Ohba M; Ohmori T
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acquired resistance to drugs targeting receptor tyrosine kinases.
    Rosenzweig SA
    Biochem Pharmacol; 2012 Apr; 83(8):1041-8. PubMed ID: 22227013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers.
    Corcoran RB; Settleman J; Engelman JA
    Oncotarget; 2011 Apr; 2(4):336-46. PubMed ID: 21505228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.
    Okimoto RA; Lin L; Olivas V; Chan E; Markegard E; Rymar A; Neel D; Chen X; Hemmati G; Bollag G; Bivona TG
    Proc Natl Acad Sci U S A; 2016 Nov; 113(47):13456-13461. PubMed ID: 27834212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway Blockade.
    Iams WT; Lovly CM
    Clin Cancer Res; 2015 Oct; 21(19):4270-7. PubMed ID: 26429980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRAF inhibitors in cancer therapy.
    Hertzman Johansson C; Egyhazi Brage S
    Pharmacol Ther; 2014 May; 142(2):176-82. PubMed ID: 24325952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticipating clinical resistance to target-directed agents : the BCR-ABL paradigm.
    Azam M; Daley GQ
    Mol Diagn Ther; 2006; 10(2):67-76. PubMed ID: 16669605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.